NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
Clinical Trials
6 trialsNCT03329001 2024-07-25
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
Tesaro, Inc.
Phase 1 Completed
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed
NCT04774406 2023-06-06
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
University Hospital, Caen
Completed
NCT02657889 2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2 Completed
NCT04774627 2021-09-23
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
University Hospital, Caen
Completed